Medexus Pharmaceuticals Inc. (TSX:MDP)

Medexus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	108.33	113.05	108.1	76.7	79.66
Revenue Growth (YoY)	-4.18%	4.59%	40.93%	-3.72%	43.52%
Cost of Revenue	44.82	47.99	42.33	33.03	32.18
Gross Profit	63.51	65.07	65.77	43.67	47.48
Selling, General & Admin	43.18	44.87	48.25	44.03	36.17
Research & Development	1.23	1.61	2.94	5.87	4.6
Operating Expenses	51.59	52.28	57.28	56.05	46.75
Operating Income	11.92	12.79	8.49	-12.38	0.73
Interest Expense	-8.2	-13.36	-13.61	-12.22	-9.82
Currency Exchange Gain (Loss)	-	-	-1.69	-0.15	1.99
Other Non Operating Income (Expenses)	1.41	2.68	2.64	23.55	-22.3
EBT Excluding Unusual Items	5.14	2.1	-4.17	-1.2	-29.39
Merger & Restructuring Charges	-0.9	-1.11	-0.88	-0.87	-2.11
Asset Writedown	-2.8	-0.89	-	-1.75	-
Pretax Income	1.44	0.11	-5.04	-3.82	-31.5
Income Tax Expense	-0.81	0.32	-6.26	-0.94	-3.24
Net Income	2.25	-0.21	1.22	-2.88	-28.26
Net Income to Common	2.25	-0.21	1.22	-2.88	-28.26
Shares Outstanding (Basic)	26	22	20	19	15
Shares Outstanding (Diluted)	27	22	21	20	15
Shares Change (YoY)	18.76%	8.76%	3.36%	30.65%	5.83%
EPS (Basic)	0.09	-0.01	0.06	-0.15	-1.86
EPS (Diluted)	0.08	-0.01	0.06	-0.15	-1.86
Free Cash Flow	23.85	18.66	-1.51	-1.28	4.92
Free Cash Flow Per Share	0.90	0.84	-0.07	-0.06	0.32
Gross Margin	58.62%	57.56%	60.84%	56.94%	59.60%
Operating Margin	11.00%	11.31%	7.85%	-16.13%	0.92%
Profit Margin	2.07%	-0.19%	1.13%	-3.75%	-35.48%
Free Cash Flow Margin	22.02%	16.51%	-1.39%	-1.67%	6.18%
EBITDA	18.94	18.44	14.37	-6.46	6.35
EBITDA Margin	17.48%	16.31%	13.30%	-8.42%	7.98%
D&A For EBITDA	7.02	5.66	5.88	5.92	5.62
EBIT	11.92	12.79	8.49	-12.38	0.73
EBIT Margin	11.00%	11.31%	7.85%	-16.13%	0.92%
Effective Tax Rate	-	301.89%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.